Small molecular compounds

Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia. H Alachkar, M B.G. Mutonga, KH. Metzeler, NFulton, et al. Oncotarget.(2014), 5(23): 12371–12382

MELK inhibitor, novel molecular targeted therapeutics for human cancer stem cells. S Chung, Y Nakamura, Cell Cycle (2013), 12 (11), 1655-1656

Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer. S Chung, H Suzuki, T Miyamoto, N Takamatsu, A Tatsuguchi, K Ueda, et la. Oncotarget (2012), 3 (12), 1629

Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family. ML Lin, JH Park, T Nishidate, Y Nakamura, T Katagiri, Breast Cancer Research (2007), 9 (1), R17

T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia. H Alachkar, M Mutonga, G Malnassy, JH Park, N Fulton, A Woods, L Meng, et al. Oncotarget (2015), 6 (32), 33410-33425

TOPK inhibitor induces complete tumor regression in xenograft models of human cancer through inhibition of cytokinesis. Y Matsuo, JH Park, T Miyamoto, S Yamamoto, S Hisada, H Alachkar, et al. Science Translational Medicine (2014), 6 (259), 259ra145-259ra145

Critical roles of T‐LAK cell‐originated protein kinase in cytokinesis. JH Park, T Nishidate, Y Nakamura, T Katagiri, Cancer science (2010), 101 (2), 403-411

Critical roles of LGN/GPSM2 phosphorylation by PBK/TOPK in cell division of breast cancer cells. C Fukukawa, K Ueda, T Nishidate, T Katagiri, Y Nakamura, Genes, Chromosomes and Cancer (2010), 49 (10), 861-872

PDZ-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer. JH Park, ML Lin, T Nishidate, Y Nakamura, T Katagiri, Cancer research (2006), 66 (18), 9186-9195

Targeting Suppressor of Variegation 3-9 Homologue 2 (SUV39H2) in Acute Lymphoblastic Leukemia (ALL). M Mutonga, K Tamura, G Malnassy, N Fulton, A de Albuquerque, et al. Translational oncology (2015), 8 (5), 368-375

SUV39H2 methylates and stabilizes LSD1 by inhibiting polyubiquitination in human cancer cells. L Piao, T Suzuki, N Dohmae, Y Nakamura and R Hamamoto, Oncotarget (2015), 10;6(19):16939-50.

Dysregulation of AKT Pathway by SMYD2-Mediated Lysine Methylation on PTEN. M Nakakido, Z Deng, T Suzuki, N Dohmae, Y Nakamura, R Hamamoto, Neoplasia (2015), 17 (4), 367-373

Critical role of lysine 134 methylation on histone H2AX for γ-H2AX production and DNA repair. K Sone, L Piao, M Nakakido, K Ueda, T Jenuwein, Y Nakamura, et al. Nature communications (2014), 5

SMYD2-dependent HSP90 methylation promotes cancer cell proliferation by regulating the chaperone complex formation. R Hamamoto, G Toyokawa, M Nakakido, K Ueda, Y Nakamura, Cancer letters (2014), 351 (1), 126-133

RB1 methylation by SMYD2 enhances cell cycle progression through an increase of RB1 phosphorylation. HS Cho, S Hayami, G Toyokawa, K Maejima, Y Yamane, T Suzuki, et al. Neoplasia (2012), 14 (6), 476-IN8

Polypeptide N-acetylgalactosaminyltransferase 6 disrupts mammary acinar morphogenesis through O-glycosylation of fibronectin. JH Park, T Katagiri, S Chung, K Kijima, Y Nakamura. Neoplasia (2011), 13 (4), 320-IN10

Critical roles of mucin 1 glycosylation by transactivated polypeptide N-acetylgalactosaminyltransferase 6 in mammary carcinogenesis. JH Park, T Nishidate, K Kijima, T Ohashi, K Takegawa, T Fujikane, et al. Cancer research (2010), 70 (7), 2759-2769

Enhanced methyltransferase activity of SMYD3 by the cleavage of its N-terminal region in human cancer cells. FP Silva, R Hamamoto, M Kunizaki, M Tsuge, Y Nakamura, Y Furukawa. Oncogene (2008), 27 (19), 2686-2692

The lysine 831 of vascular endothelial growth factor receptor 1 is a novel target of methylation by SMYD3. M Kunizaki, R Hamamoto, FP Silva, K Yamaguchi, T Nagayasu, et al. Cancer research (2007), 67 (22), 10759-10765

Enhanced SMYD3 expression is essential for the growth of breast cancer cells. R Hamamoto, FP Silva, M Tsuge, T Nishidate, T Katagiri, et al. Cancer science (2006), 97 (2), 113-118

SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. R Hamamoto, Y Furukawa, M Morita, Y Iimura, FP Silva, M Li, R Yagyu, et al. Nature cell biology (2004), 6 (8), 731-740